ClinicalTrials.Veeva

Menu

Physiotherapy in Hereditary Spastic Paraplegia

U

University Hospital Tuebingen

Status and phase

Completed
Phase 2

Conditions

Hereditary Spastic Paraplegia

Treatments

Behavioral: physiotherapy

Study type

Interventional

Funder types

Other

Identifiers

NCT03961906
Physiotherapy in HSP

Details and patient eligibility

About

Goal of this study is to develop and evaluate a physiotherapy concept that is focused on bilateral leg spasticity and aims to reduce spastic gait disturbance and to improve mobility in patients suffering from HSP.

Full description

This is a randomized single-center parallel study with a control group design. A blinded block randomization in groups of four was performed in equal parts toward the treatment (TPC) or the control (regular standard-of-care) group using randomization.com. Group assignment was kept in a closed envelope which was opened by the participant at the end of the baseline visit. Therefore both, the movement disorder specialist as well as the physiotherapist, were blinded to the randomization result for the baseline assessment up to the beginning of the first physiotherapy training session.

Therapeutic effects were evaluated at follow-up visits after 12 weeks (first visit, short-term effect) and after 26 weeks (second visit, long-term effect) comparing standard-of care with the TPC. Clinical evaluation is stated in detail below. Primary outcome assessment of this study was the change between baseline and follow-up assessment in treatment to control group in the spastic paraplegia rating scale (SPRS) score as a validated measure of disease severity (see Reference). Secondary outcome assessment was the change in walking distance in the Three-Minute-Walking test (3MW). Further exploratory outcome assessments were evaluated as effect sizes as specified below.

Enrollment

53 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • clinical diagnosis of hereditary spastic paraplegia
  • manifest spastic gait disturbance
  • remaining walking ability of at least 100m in three minutes,
  • no botulinum toxin treatment during the entire study and three months prior to study inclusion
  • no functional electronic stimulation during the study period.

Exclusion criteria

  • see above

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

53 participants in 2 patient groups

Tübingen physiotherapy concept
Active Comparator group
Description:
Will receive our therapy concept and perform self-trainings on a regular basis.
Treatment:
Behavioral: physiotherapy
controls
No Intervention group
Description:
Will receive standard-care which includes their regular physiotherapy as provided by the local therapist and can include self-trainings as well.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems